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ABSTRACT
Objective: We sought to compare the efficacy of metronidazole gel vs. triple-sulfa cream in the treatment
of bacterial vaginosis (BV).
Methods: In a double-blinded study, 247 women with symptomatic BV were randomly assigned to receive
either 5 g of 0.75% metronidazole gel twice daily for 5 days or triple-sulfa cream twice daily for 5 days.
There were 205 (96 treated with metronidazole and 109 treated with triple-sulfa) evaluable patients to
compare efficacy at the final visit. Approximately 60% of these patients had been previously treated for
BV, reflecting the recurrent nature of the disease in this patient population.
Results: At the first (12-16 days) return visit, 81/103 (79%) patients in the metronidazole group were
cured compared with 80/113 (71%) patients in the triple-sulfa cream group (P 0.333). At the final (28-35
days) return visit, 63/96 (66%) in the 96 metronidazole group remained cured compared with only 51/109
(47%) in the triple-sulfa group (P 0.02). An intent-to-treat analysis similarly showed that the cure rate
with metronidazole was superior to triple-sulfa (P-< 0.02). The clinical diagnosis demonstrated a high
correlation (88%) with the diagnosis made by an independent assessment by Gram’s stain. The side effects
reported by the patients using metronidazole gel were infrequent and mild and were similar to those
reported with triple-sulfa.
Conclusions: Metronidazole gel is a safe, effective, and well-tolerated treatment for BV.
(C) 1996 Wiley-Liss, Inc.
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ince the first report established the efficacy of
oral metronidazole for bacterial vaginosis (BV)
in 1978,1 oral metronidazole therapy has remained
the most common treatment regimen. Numerous
studies confirm the efficacy of metronidazole as
divided-dose and single-dose therapy, z-7 The cure
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rates are high at both short-term (7-14 days) (75-
90%) and long-term (28-30 days) (60-80%) follow-
tlp.4’8’9 The relatively few limitations in the use of
oral metronidazole include concern about its use
in the first trimester of pregnancy and allergy and
gastrointestinal side effects. 1’11 Recently, alterna-
tive treatments for BV have become available with
2% clindamycin cream and 0.75% metronidazole
gel. Several studies document the efficacy of intra-
vaginal clindamycin,lz-5 However, efficacy reports
with intravaginal 0.75% metronidazole have been
few,8’1,16 with only placebo-controlled comparative
study having been published to date. In the present
report, we describe a prospective, double-blinded
comparative study of the efficacy of 0.75% metroni-
dazole gel compared with intravaginal triple-sulfa
(Sultrin, Ortho Pharmaceutical, Raritan, NJ).
MATERIALS AND METHODS
Patient Population
The patient population was composed of nonpreg-
nant women, 18 years or older, attending the gyne-
cologic clinics of 10 university health care or com-
munity clinics in the United States. The women
were from diverse socioeconomic backgrounds. Ap-
proximately one-half of the patients were referred
because of recurrent BV. A woman was eligible for
enrollment in the study after a diagnosis of BV was
determined, based on a modification ofthe 4 clinical
criteria of Amsel et al. 17 These included the pres-
ence of ->20% clue cells and at least 2 of the follow-
ing 3 signs of vaginal discharge: a homogeneous
appearance, a pH of ->4.7, and a positive KOH test
for volatile amines. The exclusion criteria included
use of intrauterine contraceptive device, breast-
feeding, ongoing anticoagulant therapy, presence
of Neisseria gonorrhoeae or Chlamydia trachomatis cer-
vicitis, coexistent Candida or Trichomonas vaginalis
vaginitis, or cervical or vaginal signs of herpes sim-
ples virus infection. Further requirements for par-
ticipation in the study were abstention from sexual
intercourse during the treatment phase, use of non-
lubricated condoms during the follow-up period,
and abstention from vaginal douching and the use
of any other intravaginal drug or cream. A written
informed consent approved by the individual cen-
ter’s institutional review board was obtained from
each patient before enrollment.
Planned Sample Size
A sample size of 75 patients for each treatment
group was determined for the analysis to have at
least 80% power to detect a 30% difference in cure
rates at 30 days following treatment. The actual
sample size calculated was 38 patients for each treat-
ment group for a 2-sided test with a P of 0.05 and
power of 80%.
Blinding Method
The study was a parallel-group, double-blinded
trial. The patients were assigned to therapy by ran-
domization according to the patient numbers in in-
dividual centers.
Treatment Method
The patients were given 5 g of metronidazole gel
or triple-sulfa cream to be used twice daily for 5
days. The total dose of metronidazole for the treat-
ment regimen was approximately 375 mg. Triple-
sulfa cream is approved for the treatment of BV by
intravaginal application twice daily for 4-6 days.
Follow-Up and Evaluation
The treatment success or failure was determined
at 2 follow-up visits. Success was defined by the
absence of symptoms, a lack of 3 of the 4 clinical
criteria defined by Amsel et al., 17 and clue cells of
<20% of the desquamated epithelial cells on the
wet mount. A Gram’s stain of the vaginal discharge
was obtained at all visits to provide support of the
diagnosis of BV and to serve as a quality-control
assay. The Gram’s stains were evaluated by an inde-
pendent microbiologist blinded to the clinical diag-
nosis and treatment using parameters defined by
Nugent et al.8 The evaluations for efficacy and
safety were made at visit 2 scheduled for 12-16
days and visit 3 scheduled for 28-35 days after com-
pletion of therapy.
Statistical Analysis
The Cochran-Mantel-Haenszel statistical proce-
dure and Fisher’s exact test were used for compari-
sons in the data analysis.
RESULTS
A total of247 subjects were enrolled by 10 investiga-
tors, of these, 124 patients were assigned to receive
0.75% metronidazole gel and 123 were assigned to
receive triple-sulfa cream. Seventy-eight (63%) of
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124 patients in the metronidazole treatment group
completed the study compared with 79/123 (64%)
in the triple-sulfa treatment group. Twenty-five
(20%) of 124 patients in the metronidazole group
and 32/123 (26%) patients in the triple-sulfa group
discontinued the study at visit 2 because of unsatis-
factory therapeutic responses. The Cochran-Man-
tel-Haenszel chi-squared test for these 2 categories
revealed no statistically significant difference in the
discontinuations at visit 2 between the 2 groups.
Forty-seven percent of the subjects were white
and 47% were black. The mean age of the subjects
was 30.6 years (range 18-49 years). Approximately
60% of the subjects had previously been treated for
BV. The treatment compliance was determined by
the use of at least 25 g of medication, which is 50%
of the amount expected to be used. All evaluable
patients who returned their medication tubes met
the criteria for treatment compliance. Data are miss-
ing for 2 metronidazole and 2 triple-sulfa patients
who did not return the study medication. The mean
weight of medication was 56.3 g (range 33.5-70.4 g)
for the metronidazole treatment group compared
with 56.1 g (range 28.4-74 g) for the triple-sulfa
treatment group.
Of the 237 evaluable patients, 205 were included
in the final efficacy evaluation: 96 in the metronida-
zole group and 109 in the triple-sulfa group. The
evaluable-for-efficacy set was composed of those
patients who were evaluable at the final visit (visit
3) plus those who were evaluable at visit 2 and
diagnosed as treatment failures. According to the
protocol, efficacy was determined at 30 days after
therapy (visit 3). The patients considered failures
at visit 2 were dropped and included as failures for
visit 3. Because of this design, an intent-to-treat
analysis can be viewed in 2 ways: (method 1) inclu-
sion of patients with data who had clinical evalua-
tions at visit 3 but were considered nonevaluable
at visit 3 because of a protocol exclusion plus pa-
tients with data at visit 2 who were treatment fail-
ures, but also were considered nonevaluable at visit
2 because of a protocol exclusion or (method 2)
inclusion of all patients at visit 3. Both methods
were analyzed, but only the results analyzed by
method are presented because the results were
identical, regardless of the method used. Eight
metronidazole-treated patients and 4 triple sulfa-
treated patients were added to the efficacy set cho-
sen. Of the 96 patients considered evaluable at visit
3 in the metronidazole treatment group, 22 had no
third clinic visit because they were dropped at visit
2 as treatment failures. Therefore, the 74 patients
in this group who were clinically evaluated at visit
3 had a mean of 37.9 days in the study (range 29-68
days). In the triple-sulfa treatment group, 32/109
patients considered evaluable at visit 3 had no third
visit because they were dropped at visit 2 as treat-
ment failures. One patient failed treatment at visit
2 but was not dropped. This patient, who returned
for visit 3, was included in the group that returned
for visit 3. Therefore, 77 patients in this group were
clinically evaluated at visit 3, with a mean of 37.2
days in the study (range 24-57 days). One patient
missed visit 2 but completed visit 3 (P NS).
At the first return visit, 81/103 (79%) subjects in
the metronidazole treatment group were success-
fully treated compared with 80/113 (71%) in the
triple-sulfa treatment group (P 0.33). There were
63/96 (66%) subjects who were treatment successes
at visit 3 for the metronidazole treatment group
compared with 51/109 (47%) for the triple-sulfa
treatment group (P 0.02). When the individual
criteria for BV (clue cells, pH, KOH amine odor
test, homogeneous discharge) were evaluated, met-
ronidazole was statistically superior to triple sulfa
in eliminating 3 of the 4 criteria (clue cells, pH,
KOH amine odor test) at the final visit (P < 0.05).
Gram’s stains were obtained during 617/631 vis-
its. A weighted score was determined based on the
presence of bacterial morphotypes known to be pos-
itively or negatively associated with BV in which a
score of 7-10 corresponded to BV. A score of 0-3
corresponded to normal or cured status and 4-6
reflected intermediate flora.
19 The mean Gram’s
stain score at study entry was 7.9 in the metronida-
zole group and 7.8 in the triple-sulfa group. The
mean Gram’s stain score at the final visit (either
first or second return visit) in the metronidazole
group was 3.4, for a mean reduction of4.5, compared
with the study entry score (P < 0.001). The mean
Gram’s stain score reduction in the triple-sulfa
group from 7.8 at entry to 4.6 at the final visit was
3.2 (P < 0.001). The difference in n-lean Gram’s
stain scores of cured patients in the 2 treatment
groups (4.5 for metronidazole and 3.2 for triple sulfa)
was not statistically significant (P > 0.5). The clini-
cal diagnoses in both groups at all their visits had
high correlation (88%) with independent assess-
ments by Gram’s stains.
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Forty-one patients in the metronidazole group
and 30 in the triple-sulfa group reported mild ad-
verse events related to therapy involving mainly the
gastrointestinal and genitourinary tract (P 0.14).
Vaginal candidiasis occurred in 3 metronidazole and
2 triple-sulfa patients. One metronidazole patient
reported a severe headache questionably attribut-
able to topical metronidazole.
DISCUSSION
For almost 20 years, oral metronidazole has been
considered the treatment of choice for BV.z-7,1 Al-
though the therapeutic success rate with oral metro-
nidazole at month is 60-80%, the topical treat-
ment of BV may be preferable to systemic therapy
in some patients because of the frequency of un-
pleasant gastrointestinal side effects from oral met-
ronidazole. In addition, hematologic and neurologic
complications of oral therapy may accompany pro-
longed therapy. Ours is the first comparative thera-
peutic study of a double-blinded approach to BV
with 2 topical drugs, 0.75% metronidazole gel and
triple-sulfa cream. In the past, double-blinded stud-
ies compared oral with topical agents or topical
drug with placebo. 3,14
In the current study, the cure rate of BV with
intravaginal 0.75% metronidazole gel was superior
to the rate with intravaginal triple-sulfa cream at
the final visit (66% vs. 47%, P 0.02). When the
individual criteria for BV (clue cells, pH, KOH
amine odor test, homogeneous discharge) were
evaluated, metronidazole was statistically superior
to triple-sulfa in eliminating 3 of the 4 criteria (clue
cells, pH, KOH amine odor test) at the final visit
(P < 0.05). The clinical diagnoses in the entire
study including all investigators had high correla-
tion (88%)with independent assessments by
Gram’s stains.
The overall success rate for topical metronida-
zole in this study was 5-10% lower than that ob-
served in other trials using topical metronidazole
gel.8,6 These differences however, may be attrib-
uted to variability in the population or vaginitis
severity that frequently exists among trials as well
as to variability in the criteria for defining cure
rather than to any true difference in the efficacy of
metronidazole gel. In the current study, 60% of the
patients had previously been treated for BV. In
addition, 40% of the evaluable patients were en-
rolled by 2 investigators (J.D.S., J.T.) with clinical
practices serving patients with chronic or intracta-
ble vaginitis.
The cure of BV at the third visit (>-29 days after
the start of therapy) for women given intravaginal
triple-sulfa was significantly less than the cure in
patients given metronidazole gel. In fact, only 47%
of the triple-sulfa group appeared to have clinical
responses. However, this response rate is not as
high as it seems when the response ofBV to vaginal
placebo is considered. Intravaginal placebo ap-
peared to cure 40% of the cases of BV at 21 days
after therapy in an earlier study.
9 In the same study,
BV was cured at 21 days in 44% of the users of
intravaginal triple-sulfa cream compared with 91%
of tinidazole users (P 0.01).
9 Tinidazole has the
same spectrum of activity as metronidazole. In an-
other study, only 14% of the patients with BV re-
sponded to triple-sulfa cream.
The ineffectiveness of triple-sulfa vaginal cream
in the treatment ofBV is not difficult to understand.
Gardnerella vaginalis requires folic acid for growth
because it does not have the ability to change para-
aminobenzoic acid (PABA) to folic acid. On the
other hand, sulfa drugs act by the competitive inhi-
bition ofPABA to folic acid and only inhibit bacteria
that utilize the PABA-folic-acid pathway. In fact,
G. vagina/is is very resistant to sulfa,z The resistance
is so marked that sulfa is used to distinguish G.
vaginalis from other bacteria,z Anaerobic gram-neg-
ative rods are also not very sensitive to sulfa in
vitro, which accounts for the high rate of anaerobe
isolation following the use of triple-sulfa for BV. 1’9
This observation may explain the difference in re-
currence rates after month in the present study
between the 2 groups, 11/74 (15%) and 25/75 (33%)
for the metronidazole and triple-sulfa groups, re-
spectively.
In preparing the manuscript, we reviewed the
literature and found no reports of the treatment of
BV with triple-sulfa cream since the standardization
of the clinical diagnostic criteria by Amsel et al.7
Triple-sulfa, commonly used to treat nonspecific
vaginitis, continues to be extensively used. The
present study indicates reasonably high immediate
rates ofsymptomatic reliefwith triple-sulfa but con-
siderably poorer long-term therapeutic efficacy.
The initial safety concerns associated with the
use of systemic metronidazole in terms of carcino-
genic effects in rodentszz were found to be dose
related. Although this possibility is ofconcern, there
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is no proofof carcinogenicity, z3’z4 Nevertheless, seri-
ous side effects are well described. Topical 0,75%
metronidazole gel intravaginal therapy is associated
with a limited absorption of metronidazole and re-
duced frequency of systemic adverse reactions, as
observed in our study and other reports. 8’16 Local
side effects and complications were uncommon in
both treatment groups of our study.
In conclusion, 0.75% metronidazole vaginal gel
was superior to triple-sulfa cream in the treatment
ofBV when the patients were evaluated at approxi-
mately 30 days after therapy. The adverse events
with metronidazole were similar to those reported
with triple-sulfa, and none of the metronidazole
events were serious or severe. Triple-sulfa cream
is not particularly efficacious in eradicating BV.
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